荣昌生物(09995)：泰它西普(商品名：泰爱®)获得国药监局完全批准用于治疗类风湿关节炎患者

智通财经07-22

智通财经APP讯，荣昌生物(09995)发布公告，泰它西普(商品名：泰爱®)正式获得中国国家药品监督管理局(“NMPA”)在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎(“RA”)成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。该研究旨在评估...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2453766908?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-22 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453766908","market":"hk","top_or_hot":-1,"title":"荣昌生物(09995)：泰它西普(商品名：泰爱®)获得国药监局完全批准用于治疗类风湿关节炎患者","media":"智通财经","content":"<div>\n<p>智通财经APP讯，荣昌生物(09995)发布公告，泰它西普(商品名：泰爱®)正式获得中国国家药品监督管理局(“NMPA”)在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎(“RA”)成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。该研究旨在评估...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1154069.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>荣昌生物(09995)：泰它西普(商品名：泰爱®)获得国药监局完全批准用于治疗类风湿关节炎患者</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n荣昌生物(09995)：泰它西普(商品名：泰爱®)获得国药监局完全批准用于治疗类风湿关节炎患者\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-22 19:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1154069.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，荣昌生物(09995)发布公告，泰它西普(商品名：泰爱®)正式获得中国国家药品监督管理局(“NMPA”)在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎(“RA”)成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。该研究旨在评估...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1154069.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1969619763.USD","symbol_name":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1154069.html","article_id":"2453766908","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453766908","pubTimestamp":1721647341,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，荣昌生物 发布公告，泰它西普正式获得中国国家药品监督管理局在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688331":"荣昌生物","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1161":"生物科技","BK1583":"高瓴概念","09995":"荣昌生物","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0239":"医药制造","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK1574":"生物医药B类股"},"translate_title":"Rongchang Biotech (09995): Tatacept (trade name: Taiai ®) was fully approved by the State Food and Drug Administration for the treatment of patients with rheumatoid arthritis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1,"09995":1},"content_text":"智通财经APP讯，荣昌生物(09995)发布公告，泰它西普(商品名：泰爱®)正式获得中国国家药品监督管理局(“NMPA”)在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎(“RA”)成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。该研究旨在评估泰它西普联合甲氨喋呤治疗对甲氨喋呤疗效不佳的中重度类风湿关节炎患者的有效性和安全性。最新研究数据显示，泰它西普显着提升RA患者ACR20应答率，24周ACR20应答率67.4%，48周ACR20应答率持续提高，达72.2%;显着延缓RA患者的关节结构损害，92.8%患者24周无影像学进展，89.9%患者48周无影像学进展;显着改善RA患者的炎症水平和患者身体机能，缓解疼痛;达标(DAS28-ESR≤3.2)患者比例持续增加至48周，且安全可耐受。类风湿关节炎(RA)是一种慢性自身免疫性疾病，以侵蚀性关节炎为主要特征，发病初期的关节表现为关节晨僵、肿胀、疼痛等，最后可发生关节畸形并丧失关节正常功能，严重影响患者生活质量。根据弗若斯特沙利文报告，全球类风湿关节炎患者发病人数预计将于2025年达到4220万人(包括中国620万人)，并于2030年达到4500万人(包括中国640万人)。当前类风湿关节炎的标准治疗以抗炎类、糖皮质激素、传统免疫抑制剂及TNF-α抑制剂等药物为主，对于上述疗法无效或不耐受的患者而言，存在尚未满足的临床需求。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453766908"}